Payden & Rygel Abb Vie Inc. Transaction History

Payden & Rygel

$1.3 Billion
Q3 2024

A detailed history of Payden & Rygel transactions in Abb Vie Inc. stock. As of the latest transaction made, Payden & Rygel holds 5,010 shares of ABBV stock, worth $859,866. This represents 0.08% of its overall portfolio holdings.

Number of Shares

5,010

Previous 5,010 -0.0%

Holding current value

$859,866

Previous $859,000 15.13%

% of portfolio

0.08%

Previous 0.07%

21 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$137.6 - $154.97 $16.2 Million - $18.2 Million	-117,730 Reduced 95.92%	5,010 $776,000
Q2 2023 Aug 10, 2023	SELL	$132.51 - $164.9 $3.39 Million - $4.22 Million	-25,600 Reduced 17.26%	122,740 $16.5 Million
Q1 2023 May 10, 2023	SELL	$144.61 - $166.54 $8.67 Million - $9.98 Million	-59,930 Reduced 28.78%	148,340 $23.6 Million
Q4 2022 Feb 13, 2023	SELL	$138.31 - $165.87 $5.92 Million - $7.1 Million	-42,800 Reduced 17.05%	208,270 $33.7 Million
Q3 2022 Nov 10, 2022	BUY	$134.21 - $153.93 $603,945 - $692,685	4,500 Added 1.83%	251,070 $33.7 Million
Q2 2022 Aug 12, 2022	BUY	$137.62 - $174.96 $4.64 Million - $5.9 Million	33,700 Added 15.83%	246,570 $37.8 Million
Q1 2022 Apr 13, 2022	SELL	$131.98 - $163.75 $18.2 Million - $22.5 Million	-137,540 Reduced 39.25%	212,870 $34.5 Million
Q4 2021 Feb 11, 2022	BUY	$107.43 - $135.93 $7.46 Million - $9.44 Million	69,460 Added 24.72%	350,410 $47.4 Million
Q3 2021 Nov 15, 2021	BUY	$106.4 - $120.78 $9.49 Million - $10.8 Million	89,150 Added 46.48%	280,950 $30.3 Million
Q2 2021 Aug 06, 2021	SELL	$105.21 - $117.21 $3.51 Million - $3.91 Million	-33,400 Reduced 14.83%	191,800 $21.6 Million
Q1 2021 May 13, 2021	BUY	$102.3 - $112.62 $1.33 Million - $1.46 Million	13,000 Added 6.13%	225,200 $24.4 Million
Q4 2020 Feb 08, 2021	SELL	$80.49 - $108.67 $273,666 - $369,478	-3,400 Reduced 1.58%	212,200 $22.7 Million
Q3 2020 Nov 10, 2020	BUY	$85.91 - $100.83 $609,961 - $715,893	7,100 Added 3.41%	215,600 $18.9 Million
Q1 2020 May 04, 2020	BUY	$64.5 - $97.79 $1.01 Million - $1.54 Million	15,700 Added 8.14%	208,500 $15.9 Million
Q4 2019 Jan 31, 2020	BUY	$72.13 - $90.25 $13.2 Million - $16.5 Million	182,600 Added 1790.2%	192,800 $17.1 Million
Q1 2019 May 08, 2019	SELL	$77.14 - $90.79 $9.9 Million - $11.6 Million	-128,300 Reduced 92.64%	10,200 $822,000
Q4 2018 Jan 25, 2019	SELL	$77.85 - $96.01 $1.23 Million - $1.52 Million	-15,800 Reduced 10.24%	138,500 $12.8 Million
Q3 2018 Nov 07, 2018	SELL	$88.91 - $98.84 $960,228 - $1.07 Million	-10,800 Reduced 6.54%	154,300 $14.6 Million
Q2 2018 Aug 08, 2018	BUY	$89.78 - $106.23 $1.3 Million - $1.54 Million	14,500 Added 9.63%	165,100 $15.3 Million
Q1 2018 May 09, 2018	BUY	$92.01 - $123.21 $1.49 Million - $2 Million	16,200 Added 12.05%	150,600 $14.3 Million
Q3 2017 Nov 14, 2017	BUY	$69.85 - $89.22 $9.39 Million - $12 Million	134,400	134,400 $11.9 Million

Others Institutions Holding ABBV

# of Institutions

3,851

Shares Held

1.25B

Call Options Held

16.8M

Put Options Held

12.2M

View Full List

About AbbVie Inc.

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $303B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

More about ABBV

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Payden & Rygel, based on Form 13F filings with the SEC.

News

Stay updated on Payden & Rygel with notifications on news.

Account